COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (&gt;65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL

Jain, Preetesh; Romaguera, Jorge; Nomie, Krystle; Zhang, S.; Wang, L.; Oriabure, Onyekachukwu; Wagner‐Bartak, Nicolaus A.; Zhang, L.; Hagemeister, Fredrick; Samaniego, Felipe; Westin, Jan; Lee, H. Ju; Nastoupil, L.; Iyer, Suhasini; Parmar, S.; Ok, Chi Young; Kanagal‐Shamanna, Rashmi; Chen, W.; Thirumurthi, Selvi; Santos, David M. Cordas dos; Badillo, Maria; Fayad, Luis; Neelapu, S.S.; Fowler, Nathan; Wang, M.

doi:10.1002/hon.11_2629

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination of ibrutinib with rituximab (IR) was also explored in relapsed MCL. Jain et al 33 conducted the first single-center phase II clinical trial to analyze the efficacy and safety of IR combination as the first-line treatment for elderly MCL patients. With a median age of 71 years old, eastern cooperative oncology group (ECOG) performance score of 0–1 in 98% of the cohort, and a median number of IR cycles of 19, the best ORR was 95% (69% CR, 26% PR, 5% stable disease).…”

Section: Efficacy Of Novel Agentsmentioning

confidence: 99%

Mantle cell lymphoma management trends and novel agents: where are we going?

Savani

Huang

et al. 2022

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

The heterogeneity in disease pathology, the unpredictability in disease prognosis, and the variability in response to therapy make mantle cell lymphoma (MCL) a focus of novel therapeutic development. MCL is characterized by dysregulated expression of cyclin D1 through a chromosome t(11;14) translocation. MCL international prognostic index (MIPI), ki-67 proliferation index, and TP53 mutation status are currently utilized for prognostication. With advances in pharmacokinetic analysis and drug discovery, treatment strategy has evolved from chemotherapy to combination of targeted, epigenetic, and immune therapies. In this review, we discuss investigational and newly approved treatment approaches. In a short time, the US Food and Drug Administration (FDA) has approved five agents for the treatment of MCL: lenalidomide, an immunomodulatory agent; bortezomib, a proteasome inhibitor; and ibrutinib, acalabrutinib, and zanubrutinib, all Bruton kinase inhibitors. Epigenetic agents (e.g. cladribine and vorinostat), mammalian target of rapamycin (mTOR) inhibitors (e.g. temsirolimus and everolimus), and monoclonal antibodies and/or antibody-drug conjugates (e.g. obinutuzumab, polatuzumab, and ublituximab) are promising therapeutic agents currently under clinical trial investigation. Most recently, chimeric antigen receptor (CAR)-T cell therapy and bispecific T-cell engager (BiTE) therapy even open a new venue for MCL treatment. However, due to its intricate pathology nature and high relapse incidence, there are still unmet needs in developing optimal therapeutic strategies for both frontline and relapsed/refractory settings. The ultimate goal is to develop innovative personalized combination therapy approaches for the purpose of delivering precision medicine to cure this disease.

show abstract

Section: Efficacy Of Novel Agentsmentioning

confidence: 99%